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http://dx.doi.org/10.1016/j.stemcr.2017.03.009SUMMARYThe ability to form teratomas in vivo containingmultiple somatic cell types is regarded as functional evidence of pluripotency for human
pluripotent stem cells (hPSCs). Since the Teratoma assay is animal dependent, laborious, and only qualitative, the PluriTest and the hPSC
ScoreCard assay have been developed as in vitro alternatives. Here we compared normal hPSCs, induced hPSCs (hiPSCs) with reactivated
reprogramming transgenes, and human embryonal carcinoma cells (hECs) in these assays. While normal hPSCs gave rise to typical ter-
atomas, the xenografts of the hECs and the hiPSCs with reactivated reprogramming transgenes were largely undifferentiated andmalig-
nant. The hPSC ScoreCard assay confirmed the line-specific differentiation propensities in vitro. However, when undifferentiated cells
were analyzed by the PluriTest, only hECs were identified as abnormal whereas all other cell lines were indistinguishable and resembled
normal hPSCs. Our results indicate that pluripotency assays are best selected on the basis of intended downstream applications.INTRODUCTION
Since the advent of cellular reprogramming with exoge-
nous transcription factors (Takahashi et al., 2007; Taka-
hashi and Yamanaka, 2006), human induced pluripotent
stem cells (hiPSCs) have demonstrated important potential
for research on differentiation in human development,
modeling congenital diseases, drug target identification,
and safety pharmacology (Passier et al., 2016). hiPSC-
derived differentiated cells are also expected to play an
increasing role in human cell therapy (Inoue et al., 2014).
For optimal use, it is essential to identify hiPSC lines that
are fully reprogrammed and of high quality with proven
pluripotency in terms of differentiation to derivatives of
three germ layers. Parameters identified as affecting differ-
entiation include the genetic background (Choi et al.,
2015; Kyttala et al., 2016), X-inactivation status in female
lines (Anguera et al., 2012), the reprogramming vector
used (Choi et al., 2015), the combination of the reprogram-
ming factors (Buganim et al., 2014), their stoichiometry
(Carey et al., 2011), or their incomplete silencing after re-
programming (Ohnuki et al., 2014). A simple assay to
determine their differentiation capacity prospectively
would significantly improve the efficiency of hiPSC selec-
tion for further use.
At the molecular level, the pluripotency status is defined
by a set of commonly expressed marker genes (Interna-
tional Stem Cell Initiative et al., 2007) as well as epigenetic1340 Stem Cell Reports j Vol. 8 j 1340–1353 j May 9, 2017 j ª 2017 The Aut
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moters and the presence of bivalent domains in develop-
mental gene regions (Maherali and Hochedlinger, 2008).
Currently there is no clear consensus on the minimal re-
quirements that constitute pluripotency at the molecular
level.
Functional pluripotency, on the other hand, is defined as
the ability to form differentiated cell types of the three
germ layers.Whereasmouse PSCs are tested for their ability
to contribute to chimeric embryos or to form the entire or-
ganism in vivo, the ‘‘Teratoma assay’’ has been developed
as a surrogate for functional pluripotency in human stem
cells (Daley et al., 2009; International Stem Cell Banking
Initiative, 2009). Undifferentiated human pluripotent
stem cells (hPSCs) are injected into adult immunocompro-
mised mice, where they form ideally benign-appearing tu-
mor masses containing derivatives of the three germ layers
(Gertow et al., 2007). However, the Teratoma assay requires
mice, is costly and time consuming, and requires an expe-
rienced pathologist for analysis. The biggest drawback is
often the lack of quantification of differentiation.
An ongoing debate is whether the Teratoma assay is an
acceptable tool to evaluate pluripotency (Buta et al.,
2013; Dolgin, 2010). This has led to the search for ani-
mal-independent in vitro alternatives aswell as suggestions
of how to improve the original assay. A recently developed
microarray-based algorithm called TeratoScore quantifies
the extent to which the query sample resembles a teratomahors.
ecommons.org/licenses/by-nc-nd/4.0/).
or a primary tumor (Avior et al., 2015). The hPSC ScoreCard
assay quantifies the ability of a hPSC line to differentiate
into the three germ layers in vitro (Bock et al., 2011;
Tsankov et al., 2015). By contrast, the PluriTest algorithm
compares the global gene expression patterns of undiffer-
entiated hPSCs with those of a reference pool consisting
of numerous validated hPSCs and differentiated cells
(Muller et al., 2011).
Here we compared the outcome of these various pluripo-
tency assays using validated human embryonic stem cells
(hESCs), tetraploid hPSCs with a reported mesendodermal
differentiation bias, normal hiPSCs, hiPSCs with reacti-
vated (doxycycline [Dox]-inducible) reprogramming fac-
tors, and human embryonal carcinoma cells (hECs). We
found that hESCs, tetraploid hPSCs, and normal hiPSCs
all gave rise to typical teratomas. By contrast, tumors gener-
ated from hECs and hiPSCs with reactivated reprogram-
ming factors were largely undifferentiated and malignant.
These differences were confirmed by the TeratoScore.
However, the algorithm was unable to identify partially
differentiated tumors. Short-term in vitro differentiation
analyzed by the hPSC ScoreCard assay confirmed that the
differentiation of hiPSCs with reactivated transgenes was
severely compromised. However, in the PluriTest algo-
rithm, normal hiPSCs and differentiation-defective hiPSCs
were indistinguishable. Our data suggest that in vivo and
in vitro assays can reveal distinct features of hPSCs (molec-
ular or functional pluripotency, malignancy) and that the
choice of the assay(s) depends on the downstream applica-
tion of a particular hiPSC line.RESULTS
To evaluate and compare the performance of the standard
Teratoma assay and the in vitro/in silico pluripotency as-
says, we selected cell lines which express typical markers
of hPSCs but are expected to vary in their ability to differ-
entiate. As a standard line, we used H9 hESCs (H9) (Thom-
son et al., 1998). Secondly, a tetraploid hybrid line gener-
ated by fusion of H9 hESCs and hematopoietic stem cells
with a reported differentiation bias toward mesendoderm
was used (H9Hyb) (Qin et al., 2014). Thirdly, we generated
hiPSCs (LU07) from skin fibroblasts using a polycistronic
lentivirus with Dox-inducible transgenes OCT3/4, SOX2,
KLF4, and c-MYC (Figure 1A; Carey et al., 2009). LU07
hiPSCs are normally Dox independent and differentiate
efficiently in vitro into derivatives of all three germ layers
in the presence of fetal calf serum (FCS) (data not shown).
However, in the presence of Dox (LU07+Dox), the polycis-
tronic transgene cassette is reactivated, as evidenced by
qPCR for exogenous c-MYC, KLF4, and SOX2 (Figure 1B).
Immunofluorescent (IF) staining of the transgenic self-cleaving 2A peptide revealed that its levels vary between in-
dividual cells and that induction of the 2A peptide leads to
an increase in SOX2 protein (Figure 1C). Endogenous SOX2
expression levels were unaltered (Figure 1D), whereas
endogenous NANOG was upregulated in LU07+Dox cells
(Figures 1D and 1E). Finally we used an hEC line, which ex-
presses pluripotency markers but lacks the ability to differ-
entiate and is therefore considered nullipotent (Josephson
et al., 2007). hPSCs were cultured under defined conditions
on vitronectin in TESR-E8 medium whereas hECs were
maintained in the presence of FCS as described by Joseph-
son et al. (2007). For all assays we used undifferentiated cell
populations with R85% OCT3/4-expressing cells as deter-
mined by fluorescence-activated cell sorting (FACS) (data
not shown).
Furthermore, we tested the genetic integrity with the
COBRA assay (Szuhai and Tanke, 2006) in a fraction of cells
used for teratoma formation and for PluriTest. As expected,
hECs displayed various aneuploidies including additional
copies of (partial) chromosomes 1, 12, and 20 (Figure S1).
H9Hyb cells were tetraploid and contained one derivative
chromosome 6. H9 and H9+Dox cells were all nor-
mal whereas one out of 15 LU07 cells and one out of 20
LU07+Dox cells displayed an additional chromosome 12,
respectively (Figure S1). Long-term exposure with Dox did
not lead per se to increased aneuploidies, since undifferenti-
ated LU07+Dox cells maintained in vitro for more than
6 weeks with Dox were karyotypically normal (data not
shown).
Teratoma Formation and Analysis
To test the differentiation capacity of hPSCs and hECs in
the conventional in vivo Teratoma assay, we injected 1
million undifferentiated cells in the presence of Matrigel
subcutaneously into the flank of immunodeficient mice.
In initial experiments we found the NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) strain of mice to be more permissive
for teratoma formation than NOD.CB17-Prkdcscid/J
(NOD-SCID) (data not shown).When indicated, LU07 cells
were pretreated with Dox for 3 days prior to injection, and
mice received Dox in the drinking water 1 week before in-
jection and during the whole period of tumor formation
(LU07+Dox) (Figure 2A). To test whether Dox had any
effects independent of transgene induction, we carried
out similar experiments with H9 cells in the presence of
Dox (H9+Dox). Xenografts were harvested between 31
and 112 days when reaching a maximum volume of
2 cm3. The administration of Dox did not significantly alter
the growth rate of tumors (Figure 2B). For histological anal-
ysis, cryosections of one tumor per cell line were stained
with H&E and examined by a certified pathologist.
H9, H9Hyb, and LU07 xenografts all contained differen-
tiated structures representing the three germ layersStem Cell Reports j Vol. 8 j 1340–1353 j May 9, 2017 1341
Figure 1. Generation and Characterization of LU07 hiPSCs with Dox-Inducible Transgenes
(A) Schematic of the lentiviral construct with Dox-inducible reprogramming factors used for the generation of LU07 hiPSCs (Carey et al.,
2009). Primers for the detection of transgenic SOX2, KLF4, and c-MYC are indicated by arrows. The 2A peptide (P2A) is located between
OCT3/4 and SOX2.
(B) Expression levels of transgenic SOX2, KLF4, and c-MYC in undifferentiated LU07 or LU07 cells treated with Dox for 3 days as determined
by qPCR. Average data ± SEM (n = 4 independent experiments). *p < 0.05.
(C) Representative IF staining of undifferentiated LU07 and LU07+Dox for 2A peptide and SOX2. Nuclei were stained with DAPI.
(D) Expression levels of endogenous SOX2 and NANOG in undifferentiated LU07 or LU07 cells treated with Dox for 3 days as determined by
qPCR. Average data ± SEM (n = 4 independent experiments). *p < 0.05.
(E) Representative IF staining of undifferentiated LU07 and LU07+Dox for 2A peptide and NANOG. Nuclei were stained with DAPI.
See also Figure S1.(Figure 2C; neural rosettes and retinal pigmented epithe-
lium [ectoderm], intestinal epithelium [endoderm], carti-
lage, bone, fat, and muscle [mesoderm]). The H9+Dox
and the H9 teratomas had similar histological features. By
contrast, LU07+Dox as well as the hEC tumor were princi-
pally composed of an embryonal carcinoma-like compo-
nent, without any clearly differentiated tissues (Figure 2C).
Accordingly, the hEC and LU07+Dox tumor were diag-
nosed as ’’teratocarcinoma’’ (Damjanov and Andrews,
2007) or ‘‘embryonal carcinoma’’ according to the World
Health Organization (WHO) guidelines (Williamson
et al., 2017).
Since differentiated single cells or small groups are diffi-
cult to identify in H&E staining, we performed IF staining
with antibodies directed against bIII-tubulin (ectoderm),1342 Stem Cell Reports j Vol. 8 j 1340–1353 j May 9, 2017human a-fetoprotein (endoderm), and human PECAM-1
(mesoderm). H9, H9+Dox, H9Hyb, and LU07 teratomas
all contained areas with neurons, structures of endodermal
origin, and endothelial cells (Figure 2D). By contrast, none
of these cell types could be detected in the hEC tumor. In
the LU07+Dox xenograft, bIII-tubulin-expressing cells
were also undetectable. Endoderm and mesoderm were
evident as a small number of scattered single cells (Fig-
ure 2D), indicating that their differentiation was impaired.
To determine whether tumors still contained undifferenti-
ated cells, we stained cryosections for pluripotencymarkers
OCT3/4 and NANOG. In the hEC tumor, the great major-
ity of cells co-expressed OCT3/4 and NANOG (Figures 2D
and S2A). In the LU07+Dox xenograft, embryonal carci-
noma-like cells expressed OCT3/4 and NANOG whereas
(legend on next page)
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these markers were absent in the surrounding stromal cells
(Figures 2D and S2A). A significant proportion of the
embryonal carcinoma-like cells also showed expression of
the 2A peptide, indicating the activation of transgenes by
Dox (Figure S2B). By contrast, OCT3/4 and NANOG were
not detected in the sections of LU07, H9, H9+Dox, and
H9Hyb teratomas. In summary, the reactivation of trans-
genes largely prevented differentiation in the LU07+Dox
xenograft as determined by histological analysis. Similarly,
the hEC tumor was completely undifferentiated and both
tumors were classified as malignant. By contrast, the tera-
tomas of LU07, H9, H9+Dox, and H9Hyb lines lacked un-
differentiated cells and contained typical derivatives of
the three germ layers.
Quantification of differentiated derivatives in teratomas
by histological analysis is very laborious and subject to
sampling error (Tsankov et al., 2015). This is due to the
heterogeneous composition of the tumor (Figure 2C),
difficulties in reliably determining cell identity in H&E
staining, the analysis of only a limited number of markers
by IF staining, and potential contamination of the xeno-
graft by host mouse cells (e.g., endothelial cells of invading
blood vessels).
Recently an algorithm for the quantification of tera-
tomas, called TeratoScore, was described (Avior et al.,
2015). The TeratoScore is calculated based on the expres-
sion of a set of 100 genes representing ectoderm, endo-
derm, mesoderm, and extraembryonic tissue: scores higher
than 100 indicate an hPSC-derived teratoma, whereas a
value lower than 50 marks a tissue-specific tumor, e.g., a
medulloblastoma. Values between 50 and 100 are consid-
ered borderline for hPSCs (Avior et al., 2015). RNA was ex-
tracted from whole tumors, and processed and analyzed
with Affymetrix Human Genome (HG)-133 arrays. Both
LU07 xenografts scored in the range of typical hPSC-
derived teratomas whereas the TeratoScore results for tera-
tomas derived from the other lines were more variable (Fig-
ure 3A). Surprisingly, half of the H9 and H9+Dox teratomas
scored below the borderline (49 and 42, respectively). Eval-
uation of the individual TeratoScores showed that both
xenografts mainly consisted of ectoderm and only little
meso-, endo-, or extraembryonic tissue (Figure S3A). In
general ectoderm was the most prevalent germ layer withFigure 2. In Vivo Differentiation with the Teratoma Assay
(A) Schematic of the experimental procedure for teratoma induction.
(B) Days of xenograft growth until harvest (±SEM). For each cell line
except for H9Hyb, n = 8 and hEC, n = 6).
(C) Representative sections of H&E-stained xenografts. Arrowhead
endoderm (END). Scale bars: 200 mm.
(D) IF staining using antibodies against bIII-tubulin (ectoderm), a
NANOG (undifferentiated cells). Insets: overlay of OCT3/4 and NANOG
See also Figure S2.
1344 Stem Cell Reports j Vol. 8 j 1340–1353 j May 9, 2017the exception of H9Hyb_2 teratoma, which contained sig-
nificant amounts ofmesoderm and endoderm (Figure S3A).
As expected, the tumor of the differentiation-defective
hECs scored lowest (0.23). The scores for two LU07+Dox tu-
mors were also low (LU07+Dox_1, 24; LU07+Dox_3, 9)
whereas the score of the LU07+Dox_2 sample (226) was
similar to that of LU07.
Since the TeratoScore 100-gene list lacks markers of
undifferentiated cells, we determined the expression of
endogenous NANOG and the transgenes by qPCR in the
xenografts. In the LU07_01 teratoma, NANOG levels
were low (Figure S3B). By contrast, in the LU07+Dox_2
tumor, which had a similar TeratoScore, NANOG and
transgenes were significantly higher, indicating that a
fraction of the cells were still undifferentiated. The
NANOG and transgene levels were more elevated in
LU07+Dox_1 and _3 tumors (Figure S3B), which is in
line with their low TeratoScores. In the H9 and H9+Dox
tumors, which did not qualify as typical hPSC-derived
teratomas either, NANOG levels were low (Figure S3C),
indicating that the great majority of the cells had differ-
entiated. Taken together, the TeratoScore algorithm
confirmed our histology data showing the potential for
three-germ-layer differentiation for LU07 and the nullipo-
tency of hECs. TeratoScore results were variable for H9,
H9+Dox, and H9Hyb xenografts but at least one tumor
for each line qualified as typical teratoma. Only two out
of three LU07+Dox tumors gave a low TeratoScore, which
was possibly linked to variable levels of transgene induc-
tion. Importantly, the lack of pluripotency markers in
the TeratoScore 100-gene list can lead to similar scores
for xenografts, which grossly differ in the proportion of
undifferentiated cells.
For each cell line we analyzed the tumors used for Terato-
Score as well as additional samples with the more
commonly used Illumina HT-12 platform. In line with
our histology data, two clusters emerged based on whole
transcriptome data: the differentiation-defective and ma-
lignant hEC and LU07+Dox tumors on the one hand and
the teratomas derived from H9Hyb, H9, H9+Dox, and
LU07 on the other (Figure 3B). Within each cluster, xeno-
grafts generated from the same cells were highly similar.
Compared with normal teratomas (LU07, H9, H9+Dox),the same batch of cells were injected into six to eight mice (n = 7
s indicate derivatives of mesoderm (MES), ectoderm (ECT), and
-fetoprotein (AFP, endoderm), PECAM-1 (mesoderm), OCT3/4, and
. Nuclei were stained with DAPI. Scale bars, 75 mm.
Figure 3. Microarray Analysis of Teratomas
(A) TeratoScore results: >100, teratoma of a typical hPSC; 100–50, borderline hPSC teratoma; <50, tissue-specific tumor.
(B) Hierarchical clustering based on global gene expression for the same xenografts as in (A) with additional samples.
(C) Venn diagram of differentially expressed genes of hEC and LU07+Dox tumors compared with H9, H9+Dox, and LU07 teratomas (false
discovery rate adjusted p value <0.05, log2 fold change >0.5).
(D) Significantly upregulated pluripotency- and/or cancer-associated genes in LU07+Dox and hEC tumors in fold change compared with
H9, H9+Dox, and LU07 teratomas (FDR adjusted p < 0.05).
See also Figure S3.more than 6,500 genes were differentially expressed in the
LU07+Dox or the hEC tumor and a large proportion were
shared by both (Figure 3C). Various differentially expressed
genes have known roles in pluripotency and malignancy,
for exampleNANOG,OCT3/4,CD30,UTF1, and LIN28 (Fig-
ure 3D). Of note, the upregulatedOCT3/4 in the LU07+Dox
tumor is endogenous since the mouse transgenes are not
detected by the human-specific microarray platform. The
microarray data are in line with our IF staining results for
OCT3/4 andNANOG (Figure 2D). In addition, immunohis-
tochemistry staining showed increased NANOG and CD30
protein levels in the LU07+Dox and hEC xenografts (Fig-
ure S2A). It has been shown that CD30, a member of the
tumor necrosis factor receptor family, is expressed on
transformed hESCs (Herszfeld et al., 2006) and is a well-
recognized diagnostic marker for hECs (Ulbright et al.,
2014).Since LU07+Dox and hEC xenografts showed histologi-
cally malignant features, we analyzed the tumors with a
recently published qPCR assay for aneuploidies commonly
found in hPSC cultures (Baker et al., 2016). As shown in Fig-
ure S2C, hEC tumors contained additional copies of (par-
tial) chromosomes 1, 12, and 20. By contrast, aneuploidies
were not detected in the LU07+Dox xenografts or in any of
the other teratomas (Figure S2C).
Taken together, the microarray data confirmed that
LU07+Dox tumors with reactivated transgenes and hEC tu-
mors are highly undifferentiated and display features of
malignancy. However, common aneuploidies were only
identified in the hEC xenografts.
In Vitro Differentiation
Recently, the hPSC ScoreCard assay was proposed as a sur-
rogate for the Teratoma assay to assess the functionalStem Cell Reports j Vol. 8 j 1340–1353 j May 9, 2017 1345
pluripotency of hPSCs. It quantifies hPSC in vitro differen-
tiation potential by measuring the expression of nine self-
renewal genes and of 70 genes representing specific line-
ages by qPCR. The hPSC ScoreCard algorithm compares
the expression levels with those of 13 undifferentiated
standard hPSCs, including H9, then provides a single score
for the query sample for self-renewal and each of the three
germ layers (Bock et al., 2011; Tsankov et al., 2015).
We first performed endodermal differentiation using a
monolayer protocolwithDox added toH9 and LU07where
indicated (Figure 4A). After 5 days, cells were analyzed by
FACS and the hPSC ScoreCard assay. As expected, no reduc-
tion ofOCT3/4-expressing cells was observed in hECs (87%
± 3.8%, Figure S4A). LU07+Dox cells maintained a similar
percentage of OCT3/4+ cells (85% ± 2.6%) indicating
impaired differentiation (Figures 4B and S4A). By contrast,
the proportion of OCT3/4+ cells was significantly smaller
for LU07 cells (58% ± 8.1%) as well as for H9, H9+Dox,
and H9Hyb (41% ± 15.2%, 48% ± 18.2%, and 22% ±
23.0%, respectively, Figure S4A). For transcriptional anal-
ysis, total RNA was isolated and qPCR performed with the
commercially supplied hPSC ScoreCard plates. As shown
in Figure 4E, LU07, H9, H9+Dox, andH9Hyb all downregu-
lated self-renewal genes and exclusively differentiated into
endoderm. All lines had similar endodermal scores despite
the previously reported differentiation bias of H9Hyb (to-
ward mesendoderm) and H9 cells (toward ectoderm), sug-
gesting that perhaps newer endoderm differentiation pro-
tocols are more effective. By contrast, levels of self-
renewal genes were unchanged or only slightly downregu-
lated in hECs and LU07+Dox cells, respectively. Both cell
lines were unable to give rise to endoderm (Figure 4E).
Neither ectoderm nor mesoderm was induced in LU07+-
Dox. Interestingly, for hECs the mesoderm score was upre-
gulated. We found a similar mesoderm score for hECs
cultured in maintenance medium (data not shown). RGS4
andNKX2.5were among the highly upregulated ScoreCard
mesodermal genes (data not shown). This is in line with
earlier findings indicating that RGS4 and NKX2.5 expres-
sion is more than 50-times higher in the same hEC line
compared with a standard hESC line (Josephson et al.,
2007). Thus, despite the expression of self-renewal genes,
hECs may co-express certain mesodermal genes indepen-
dent of the culture condition.
To test the capacity for ectodermal differentiation, we
next performed monolayer differentiation (Figure S4B).
However, hPSC ScoreCard analysis showed that H9Hyb
was the only line with an elevated average score for ecto-
derm (Figure S4C) despite a reported mensendodermal dif-
ferentiation bias (Qin et al., 2014). By contrast, H9+Dox
cells did not give rise to ectoderm and for H9 and LU07
the average ectoderm score was low to borderline, respec-
tively (Figure S4C). Previously, H9 embryoid bodies (EBs)1346 Stem Cell Reports j Vol. 8 j 1340–1353 j May 9, 2017have been shown to differentiate efficiently into the neuro-
ectodermal lineage (Bock et al., 2011) suggesting that this
particular ectodermal differentiation protocol was not
optimal for analysis by the hPSC ScoreCard. As an alterna-
tivemethod, we used the Stemdiff Neural Induction system
whereby spin-EBs are cultured in suspension for 5 days
followed by 4 days of adherent culture (Figure 4A). FACS
analysis revealed a significant reduction in OCT3/4+ cells
for LU07, whereas in the presence of Dox the proportion
of OCT3/4-expressing cells was similar to that of undiffer-
entiated cells (42% ± 9.8% and 92.8% ± 2.3%, respectively;
Figures 4C and S4A). In linewith this, the self-renewal score
for LU07 was low whereas self-renewal markers were main-
tained in LU07+Dox (Figure 4E). LU07+Dox did not give
rise to ectoderm or derivatives of any other germ layer. By
contrast, the differentiation of LU07 was confirmed by an
elevated score for ectoderm as well as for mesoderm. The
latter may be due to formation of neural crest cells in paral-
lel with the neural progenitors. H9 cells differentiated
exclusively into ectoderm (Figure 4E).
Finally, we tested the mesodermal differentiation capac-
ity of LU07 and LU07+Dox using a monolayer differentia-
tion protocol (Figure 4A). At day 5 of differentiation, the
percentage of cells expressing high levels of OCT3/4 was
reduced in both LU07 and LU07+Dox (6% ± 1.4% and
53% ± 9.2%, respectively; Figure S4A) compared with un-
differentiated cells. Nevertheless, LU07+Dox cells still
showed moderate OCT3/4 expression levels whereas the
expression was low in LU07 cells (Figure 4D). The hPSC
ScoreCard analysis indicated a pronounced downregula-
tion of self-renewal genes in cells with and without Dox
(Figure 4E). Although Doxwas unable to prevent the differ-
entiation of LU07+Dox cells towardmesoderm, the average
mesodermal induction was significantly lower than in
LU07 cells (Figure 4E). Taken together, hPSCs efficiently
differentiated into endoderm (H9, H9+Dox, H9Hyb,
LU07), ectoderm (H9, LU07), and mesoderm (LU07). By
contrast, the reactivation of transgenes by addition of
Dox maintained LU07+Dox in the undifferentiated state
and prevented differentiation into endoderm or ectoderm.
However, mesoderm induction was only slightly reduced.
In conclusion, the ScoreCard assay can assess pluripotency
at a functional level. By providing a score for self-renewal
and each of the three germ layers, the hPSC ScoreCard
assay can distinguish normal hPSCs from cells with a differ-
entiation defect. Our in vitro differentiation data for LU07
and LU07+Dox cells confirmed the teratoma data with
respect to pluripotency.
Pluripotency Analysis of Undifferentiated Cells
A microarray-based tool using undifferentiated hPSCs has
also been described as another in vitro alternative to the
Teratoma assay (Muller et al., 2011, 2012). This PluriTest
Figure 4. hPSC ScoreCard Analysis of In Vitro Differentiations
(A) Schematics of endodermal, ectodermal, and mesodermal differentiation procedures.
(B–D) Representative FACS histogram of OCT3/4 in LU07 cells before differentiation (gray area) and in LU07 (black line) and LU07+Dox
cells (dashed line) at the end of endodermal (B), ectodermal (C), and mesodermal (D) differentiation.
(E) hPSC ScoreCard results for endodermal differentiation (upper panel), ectodermal differentiation (middle panel), and mesodermal
differentiation (lower panel). Left: hPSC ScoreCard result icons ‘‘+’’ (positive), ‘‘O’’ (borderline), or ‘‘–’’ (negative) are displayed and color
coded green (self-renewal), blue (ectoderm), orange (mesoderm), and purple (endoderm). Icons represent the average of biological
repeats (endoderm: n = 4 except for hEC, H9+Dox, and H9Hyb [n = 3]; ectoderm: LU07, n = 5; LU07+Dox, n = 3, H9, n = 2; mesoderm: n = 4).
Right: Average scores (±SEM) of the same differentiations. Blue, downregulated; white, unchanged; red, upregulated. *p < 0.05.
See also Figure S4.
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Figure 5. PluriTest and Microarray Analysis of Undifferentiated Cells
(A) PluriTest results (n = 4 for LU07 and LU07+Dox; n = 3 for hEC, H9, H9+Dox, H9Hyb, biological repeats). The background encodes an
empirical density map indicating pluripotency (red) and novelty (blue); thresholds for pluripotency (20, horizontal) and novelty (1.67,
vertical) are indicated with dashed lines.
(B) Hierarchical clustering based on global gene expression for the same samples as in (A).
(C) Venn diagram of up- and downregulated differentially expressed genes in hECs and LU07+Dox compared with undifferentiated H9,
H9+Dox, and LU07 (filled bars: FDR adjusted p < 0.05, log2 fold change >0.5).
(D) Significantly up- and downregulated pluripotency- and/or cancer-associated genes in undifferentiated LU07+Dox cells and hECs in fold
change compared with H9, H9+Dox, and LU07 cells (filled bars: FDR adjusted p < 0.05; empty bar, not significant).
See also Table S1.algorithm uses genome-wide transcriptional profiles of
more than 260 validated hPSCs (223 hESCs and 41 hiPSCs)
as well as differentiated cell types and developing and adult
tissues as a reference dataset for comparison with the query
sample. A Pluripotency Score above 20 and a Novelty Score
below 1.67 indicate that cells resemble typical hPSCs and
that they are similar to normal hPSCs, respectively (Muller
et al., 2011, 2012). Analysis of undifferentiated cells by the
PluriTest algorithm revealed that H9, H9+Dox, H9Hyb,
LU07, and LU07+Dox cells all resembled validated normal
hPSCs (Figure 5A). Cells with or without Dox treatment
(3 days) were indistinguishable and had similar Pluripo-
tency and Novelty Scores (Table S1). By contrast, all hEC
samples clustered separately and had a borderline or low1348 Stem Cell Reports j Vol. 8 j 1340–1353 j May 9, 2017Pluripotency Score and an elevated Novelty Score (Fig-
ure 5A and Table S1). This is in line with our own and pub-
lished data showing that hECs have a highly aberrant kar-
yotype (Figure S1A) and that their expression levels of
pluripotency markers are markedly different from normal
hPSCs (Josephson et al., 2007; Muller et al., 2011). On
the other hand, the PluriTest algorithm did not indicate
that the Novelty or Pluripotency Score was altered for the
tetraploid H9Hyb cells (Figure 5A and Table S1). In fact
the global gene expression pattern of hPSC hybrids has
been shown to be highly similar to that of their diploid
parental hPSCs (Qin et al., 2014).
Since the PluriTest algorithm gave comparable results for
all hPSCs except the hECs, we asked whether whole
transcriptome analysis would reveal subtle differences,
especially for the LU07+Dox cells with the reactivated
transgenes. Hierarchical clustering analysis of whole tran-
scriptome data confirmed that hECs are most distinct
from H9Hyb, H9, and LU07 with or without Dox treat-
ment. However, within the second cluster, three out of
four LU07+Dox samples represented a subgroup slightly
different from non-treated LU07 and the other hPSC lines
(Figure 5B). Compared with H9, H9+Dox, and LU07, we
foundmore than 500 genes to be upregulated or downregu-
lated in undifferentiated LU07+Dox cells, of which 387
overlapped with hECs, respectively (Figure 5C). Of note,
the human-specific Illumina microarray used for PluriTest
cannot detect the Dox-inducible transgenes, which are en-
coded by mouse cDNAs. The microarray expression levels
of the endogenous versions of the reprogramming factors
(OCT3/4, MYC, KLF4, SOX2) were not significantly
different between LU07 and LU07+Dox (data not shown
and Figure 1D). However, additional pluripotency-associ-
ated markers including endogenous NANOG, UTF1,
GDF3, GAL, LEFTY2, CD9, and NODAL (International
Stem Cell Initiative et al., 2007) were significantly upregu-
lated in LU07+Dox cells (Figure 5D). The same genes
(except GAL) were expressed at even higher levels in
hECs. In hECs approximately 5,500 genes were up- or
downregulated compared with H9, H9+Dox, and LU07
cells (Figure 5C), and it seems that this higher number of
deregulated genes led to borderline or low Pluripotency
Scores (Figure 5A and Table S1).
Taken together, the Pluripotency and the Novelty Score
designated hECs as being abnormal. By contrast, PluriTest
qualified H9, H9+Dox, H9Hyb, LU07, and LU07+Dox
cells as pluripotent and normal based on their gene expres-
sion patterns in the undifferentiated state. However, the
PluriTest was unable to reveal subtle differences in the
expression of endogenous pluripotency-associated genes
between LU07 and LU07+Dox, which together with the re-
activated reprogramming factors are likely to affect func-
tional pluripotency.DISCUSSION
In a side-by-side comparison we analyzed several hPSC
lines with distinct differentiation capacities using the Tera-
toma assay and various in vitro alternatives such as the
PluriTest and the hPSC ScoreCard. With the LU07+Dox
cells we developed an experimental model of differentia-
tion-defective hPSC lines (Figure 1), which we used to chal-
lenge current state-of-the-art pluripotency assays.
H9 hESCs, H9Hyb hPSCs, and LU07 hiPSCs all formed
teratomas containing the three germ layers and lacking
undifferentiated cells as shown by H&E and IF staining(Figure 2). By contrast, hEC and LU07+Dox tumors closely
resembled each other in being mainly composed of embry-
onal carcinoma-like cells still expressing pluripotency
markers.
Quantitative analysis of the xenografts by TeratoScore
confirmed that LU07 hiPSCs, H9 hESCs, and H9Hyb hPSCs
can give rise to typical hPSC-derived teratomas (Figure 3A).
TeratoScore also confirmed the nullipotency of hECs and a
differentiation defect in two out of three LU07+Dox tu-
mors. The third LU07+Dox tumor received a TeratoScore
similar to that of the LU07 teratoma. However, we found
that these tumors varied substantially in their NANOG
expression levels, indicating that a significant proportion
of undifferentiated cells was still present in the LU07+Dox
tumor. The fact that pluripotencymarkers are not included
in the TeratoScore 100-gene list can lead to similar scores
for fully and partially differentiated tumors. Moreover, we
found variable TeratoScore results for H9, H9+Dox, and
H9Hyb xenografts, indicating a typical teratoma, a border-
line tumor, or even a primary tumor (Figure 3A). It seems
advisable that at least two teratomas derived from the
same cells should be analyzed with TeratoScore to reduce
the risk of falsely categorizing cells as non-pluripotent.
In general, our histologically classical defined teratomas
containing tissues from all three germ layers scored lower
than the average TeratoScore reported by Avior et al.
(2015). Although attempts have been made, the Teratoma
assay has not been standardized to date (Gropp et al.,
2012). The resulting variability in experimental procedures
and histological interpretation has hampered the compar-
ison of results between different laboratories (Muller et al.,
2010). Indeed, Avior et al. (2015) cultured hPSCs on MEFs
and injected 3 3 106 cells under the kidney capsule of
NOD-SCID mice, whereas our tumors were induced with
1 3 106 TESR-E8 cells injected subcutaneously into NSG
mice.
Our histological analysis of tumors revealed that the
LU07+Dox tumor resembled the hEC tumor and was
therefore classified as malignant teratoma or teratocarci-
noma (Muller et al., 2010) or, according to the WHO
nomenclature for human germ cell tumors, as a typical
‘‘embryonal carcinoma’’ (Williamson et al., 2017). We
confirmed this diagnosis by immunohistochemistry stain-
ing for OCT3/4, NANOG, SOX2, anti-cytokeratin (AE1/
AE3), and CD30 (Figure S2A and data not shown) (Ulbright
et al., 2014). Characteristics of malignancy are rarely
discussed when interpreting results from the Teratoma
assay. We believe that the application of the WHO human
germ cell tumor classification could be more useful for a
detailed evaluation of elements that are associated with
malignancy.
In addition to the histology data, clustering analysis
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LU07+Dox tumors were more similar to embryonal carci-
noma-like tumors than to normal teratomas (Figure 3B).
The transformation of LU07+Dox cells toward a malignant
phenotype in vivo is likely to be caused by the prolonged
reactivation of the reprogramming factors, which have all
been shown to play a role in cancer. For example, c-MYC
is a known oncogene and its abnormal expression has
been shown to affect genomic integrity (Barlow et al.,
2013). Indeed we identified several aneuploidies in hEC xe-
nografts. However, LU07 or LU07+Dox tumors did not
reveal any typical aneuploidies (Figure S2C) despite the
fact that a fraction of the undifferentiated cells used for
injection had an additional chromosome 12 (Figure S1).
The qPCR assay used for detection of aneuploidies only
covers (parts of) the chromosomes typically affected in
hPSC cultures (chromosomes 1, 12, 17, and 20). Therefore,
we cannot rule out that the malignant phenotype of
LU07+Dox tumors is (partially) caused by karyotypic
abnormalities affecting other regions or the remaining
chromosomes.
In summary, the Teratoma assay can reveal the differen-
tiation capacity of hPSCs in vivo and provides valuable in-
formation on the malignant potential of cells.
Our in vitro differentiation data, analyzed by the hPSC
ScoreCard assay, confirmed the in vivo finding that
LU07+Dox cells were unable to differentiate into endo-
derm and ectoderm and that they maintained the expres-
sion of pluripotency markers (Figure 4E). Furthermore,
our hiPSC ScoreCard data confirmed that LU07 cells were
able to differentiate into derivatives of all three germ layers
in vitro (Figure 4E), which is in line with the teratoma data
(Figure 2). However, the hPSC ScoreCard data did not
confirm the differentiation biases reported by others previ-
ously or indicated by our TeratoScore data. For example,
the H9 cells (with a reported differentiation bias toward
ectoderm [Bock et al., 2011]) and LU07 cells (ectodermal
differentiation bias indicated by TeratoScore) received
endodermal scores similar to those of H9Hyb cells. Like Ter-
atoScore, the hPSC ScoreCard is based on a limited number
of genes representing the three germ layers. The question
remains of whether assays which rely on a relatively
restricted set of markers can indeed detect (subtle) lineage
biases between cell lines.
It has been questioned whether in vitro assays that rely
on complex and expensive protocols for directed differen-
tiation or on spontaneous differentiations with EBs, which
often contain undifferentiated cells in their core, would be
useful for the assessment of pluripotency of hPSCs (Avior
et al., 2015). Here we show that relatively simple, commer-
cially available, short differentiation protocols based on
cells in a monolayer (endoderm, mesoderm) or on short-
term EBs consisting of a defined cell number (ectoderm)
can be used for ScoreCard analysis. Each protocol required1350 Stem Cell Reports j Vol. 8 j 1340–1353 j May 9, 2017an initial optimization for each line in terms of cell number
for plating or for incorporation into EBs, but then resulted
in efficient differentiation toward the respective germ layer
in multiple independent experiments.
Taken together, the hPSC ScoreCard data revealed the
functional pluripotency of the LU07 cells and the differen-
tiation deficiency of the LU07+Dox cells. The assay
confirmed the teratoma data but is animal independent,
much quicker, and quantitative.
An ideal assay to predict the functional pluripotency
would be independent of in vitro and in vivo differentia-
tion assays and exclusively rely on the analysis of undiffer-
entiated cells. Currently there is no clear consensus on the
minimal requirements for characterization of hPSCs at the
molecular level (Chan et al., 2009). In addition,markers are
demonstrated at mRNA or protein level and methods vary
between qualitative (IF staining) or quantitative (FACS,
qPCR). This lack of standardization makes it difficult to
compare results between different research laboratories.
In this respect the microarray-based bioinformatics assay
PluriTest is a significant advance: it analyzes the global
gene expression of a query sample and provides a quantita-
tive result (Muller et al., 2011).
PluriTest has been shown to identify normal hPSC and
highlight partially reprogrammed cells or nullipotent,
karyotypically abnormal hECs as different from a large
number of hPSC lines (Muller et al., 2011). However,
LU07+Dox cells had a normal Pluripotency Score, despite
their severely compromised differentiation capacities
in vitro and in vivo. The inability of PluriTest to distinguish
LU07+Dox cells with reactivated transgenes from LU07
cells partially results from the inducible reprogramming
factors being encoded by mouse cDNAs, which are not de-
tected by the human-specific microarray platform on
which PluriTest is based. This could potentially concern
any other integrating reprogramming vector with mouse
transgenes.
A total of 508 endogenous genes were differentially ex-
pressed in LU07+Dox cells when compared with LU07,
H9, and H9+Dox cells including several pluripotency-
and/or cancer-related genes (Figure 5D). However, the
fact that the Pluripotency Scores of LU07+Dox cells and
LU07 cells were indistinguishable indicates that the
PluriTest algorithm trained on a dataset from bona fide
PSCs considered the global gene expression profile of
LU07+Dox cells to be within the range of normal hPSCs.
By contrast, in hECs, a total of more than 5,500 genes
were different (Figure 5C). This higher degree of deregula-
tion in global gene expression resulted in Pluripotency
Scores at or below the threshold of normal hPSCs. Similar
to LU07+Dox cells, a number of pluripotency-associated
genes were upregulated in hECs; in general their
induction was higher than in LU07+Dox cells (Figure 5D).
It seems likely that the differentiation deficiency of
LU07+Dox cells was caused by upregulation of the endo-
genous pluripotency-associated genes in combination
with the reactivated transgenes. The overlap of approxi-
mately 400 deregulated genes shared between hEC and
LU07+Dox cells suggest the possibility that given an exter-
nally validated dataset, additional models and scores
within the PluriTest-framework could be trained to reliably
detect other potentially differentiation-defective hPSC cell
lines with properties similar to those of LU07+Dox cells.
In conclusion, the PluriTest provides quantitative infor-
mation regarding whether a given cell line resembles
normal hPSCs at a global molecular level. Higher-resolu-
tion RNA-sequencing data and the addition of epigenetic
and microRNA profiles are likely to further improve the
quality control of undifferentiated hPSCs. Short-term
in vitro differentiation can reveal differences in functional
pluripotency which are similar to the in vivo data. We
therefore propose PluriTest in combination with the
hPSC ScoreCard for routine characterization of hPSCs
used for in vitro disease modeling and drug testing. Given
the large numbers of hiPSC lines expected to be generated
in the future, this would lead to a significant reduction of
animal experiments and contribute to implementation of
the ‘‘3Rs’’ policy (Replacement, Reduction, Refinement).
Remarkably, the Teratoma assay is the only one of the three
methods able to reveal malignant potential; this is a critical
exclusion criterion for future hPSC clinical application.
Indeed, the Teratoma assay has been proposed as a readout
for tumorigenicity, although a quantitative analysis is
currently lacking (Bulic-Jakus et al., 2016). However, the
usefulness of a xenograft model for the prediction ofmalig-
nancy in autologous clinical applications needs to be inves-
tigatedmuchmore in detail. In this respect mice with a hu-
manized immune systemmay represent a further advance.
Ideally, markers indicating potential malignancy could
already be identified in undifferentiated cells.
In general, for better comparison of results between lab-
oratories, all assays should be performed in standardized
ways, e.g., with defined culture conditions for undifferenti-
ated cells, a simple and robust set of in vitro differentiation
protocols, and standardized procedures for teratoma induc-
tion and analysis.EXPERIMENTAL PROCEDURES
Full details are provided in Supplemental Experimental
Procedures.
Cell Culture
All hPSCs were maintained on Vitronectin-XF in TESR-E8medium
(STEMCELLTechnologies). LUMC007iCTRL01 was cultured in the
absence of Dox unless otherwise stated. hECs were maintained inDMEM/F12 medium (Life Technologies) containing 10% FCS
(Gibco).
In Vitro Differentiation Assays
Monolayer differentiation of hPSCs into neural stem cells was per-
formedwithNeural InductionMedium (Life Technologies). Neural
progenitor cells were generated by using the STEMdiff Neural Sys-
tem EB protocol. For differentiation into endoderm, the TESR-E8
optimized STEMdiff Definitive Endoderm Kit was used. Mesoderm
differentiation was performed using STEMdiff mesoderm induc-
tion medium (all from STEMCELL). All differentiations were per-
formed according to the manufacturer’s protocol. Dox was added
when indicated (Figures 4A and S4B).
Teratoma Assay
Eight- to 10-week-old male NSG mice (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ, Charles River) were used for injections. Cells
(1 3 106) were injected subcutaneously in the flank region. Tumor
growth was monitored weekly by palpation, and mice were eutha-
nized when tumors reached a volume of %2 cm3. Animal experi-
ments were approved by the Leiden University Medical Center
(LUMC) Animal EthicsCommittee. The LUMC is an institutional li-
cense holder according to Dutch Law on animal experimentation.
Immunofluorescent Staining and
Immunohistochemistry
Staining procedures were performed according to standard proced-
ures using 8-mm frozen sections or paraformaldehyde-fixed
cultured cells. Primary antibodies were applied overnight at 4C,
followed by the secondary antibodies for 1 hr at room temperature.
For antibodies, see Supplemental Experimental Procedures.
RNA Isolation and qRT-PCR
Xenografts were homogenized in RA1 buffer (Macherey-Nagel)
with 1% b-mercaptoethanol using an Ultra-Turrax T8 homoge-
nizer (IKA Labortechnik). An aliquot of the homogenate was
used for RNA isolation using the NucleoSpin RNA kits (Ma-
cherey-Nagel), including a DNase-digestion step, according to
the manufacturer’s instructions. Quantitative expression analysis
was performed on a Bio-Rad C1000 Thermal Cycler equipped
with a CFX96/384 Real-Time System, with the iQ SYBR Green kit
(Bio-Rad). Template cDNA was prepared from 1 mg of total RNA
using the iScript cDNA synthesis kit (Bio-Rad). Expression of the
target genes was normalized to hARP.
hPSC ScoreCard Assay
Template cDNA was prepared from 1 mg of RNA using the High-
Capacity cDNA Reverse Transcription kit (Applied Biosystems) ac-
cording to the manufacturer’s protocol. hPSC ScoreCard assays
(Life Technologies) were run according to manufacturer’s instruc-
tions on a Viia7 RT-PCR System (Applied Biosystems) using the
‘hpsc-ScoreCard-template-viia-7-384-well’ template.
Microarray Analysis
cRNA was labeled and hybridized to Affymetrix Human Genome
U133 Plus 2.0 arrays (Dutch Genomics Service & Support Provider,Stem Cell Reports j Vol. 8 j 1340–1353 j May 9, 2017 1351
University of Amsterdam). RNA for analysis with PluriTest and
from xenograft samples was labeled and hybridized onto the Illu-
mina Human HT-12 v4 array by GenomeScan.ACCESSION NUMBERS
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